Part I: Milestones in personalised medicine--imatinib.
Gambacorti-Passerini
Carlo
C
Clinical Research Unit, University of Milano Bicocca, San Gerardo Hospital, Monza, Italy. carlo.gambacorti@unimib.it
D000970:Antineoplastic Agents / Q000266:history* / Q000627:therapeutic use; D001549:Benzamides; D049673:History, 20th Century; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000266:history*; D018579:Patient Selection; D010879:Piperazines / Q000266:history* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000266:history* / Q000627:therapeutic use; D011743:Pyrimidines / Q000266:history* / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate